TABLE A1.

Subsequent Therapies in the Sunitinib and Cabozantinib Arms

Subsequent Therapy	Sunitinib (n = 20), No. (%)	Cabozantinib (n = 17), No. (%)
Systemic therapies
Anti-VEGF alone	7 (35)	5 (29)
mTOR inhibitor alone	1 (5)	—
PD-1 inhibitor	9 (45)	7 (41)
CTLA-4 inhibitor	2 (10)	—
Anti-VEGF plus ICI	3 (15)	1 (6)
Anti-VEGF plus mTOR inhibitor	—	6 (35)
Other	1 (5)	3 (18)
Local therapies
Radiation therapy	1 (5)	1 (6)
Surgery	1 (5)	—

NOTE. Six patients on the sunitinib arm received cabozantinib as subsequent therapy, either alone or in combination with PD-(L)1 inhibitors.

Abbreviations: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; ICI, immune checkpoint inhibitor; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.